Alternative approaches such as treatment with engineered IgE antibodies against cancer antigens may activate effector cells by signaling through IgE Fc receptors, as a means of bypassing IgG4-mediated Fc blockade mechanisms. This evidence concerns the gene IGHE and cancer.